Click for best price
Postpemic Era Duchenne Muscular Dystrophy Drugs Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
(Post-pandemic Era)-Global Duchenne Muscular Dystrophy Drugs Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Duchenne Muscular Dystrophy Drugs industry at home and abroad, estimate the overall market scale of the Duchenne Muscular Dystrophy Drugs industry and the market share of major countries, Duchenne Muscular Dystrophy Drugs industry, and study and judge the downstream market demand of Duchenne Muscular Dystrophy Drugs through systematic research, Analyze the competition pattern of Duchenne Muscular Dystrophy Drugs, so as to help solve the pain points of various stakeholders in Duchenne Muscular Dystrophy Drugs industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Duchenne Muscular Dystrophy Drugs Market by Research Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Duchenne Muscular Dystrophy Drugs Market?
Biogen
Roche
Daiichi Sankyo
Pfizer
Cumberland Pharmaceuticals
Santhera Pharmaceuticals
Taiho Pharmaceutical
Teijin Pharma
Akashi Therapeutics
Sarepta Therapeutics
BioMarin
Fibrogen Inc
Nobelpharma Co. Ltd
Eloxx Pharmaceuticals
Major Type of Duchenne Muscular Dystrophy Drugs Covered in Research report:
Molecular-based Therapies
Steroid Therapy
Other
Application Segments Covered in Research Market
Hospitals
Clinics
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Duchenne Muscular Dystrophy Drugs Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
94 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Duchenne Muscular Dystrophy Drugs Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Duchenne Muscular Dystrophy Drugs Market by Value
2.2.1 Global Duchenne Muscular Dystrophy Drugs Revenue by Type
2.2.2 Global Duchenne Muscular Dystrophy Drugs Market by Value
2.3 Global Duchenne Muscular Dystrophy Drugs Market by Sales
2.3.1 Global Duchenne Muscular Dystrophy Drugs Sales by Type
2.3.2 Global Duchenne Muscular Dystrophy Drugs Market by Sales
3. The Major Driver of Duchenne Muscular Dystrophy Drugs Industry
3.1 Historical & Forecast Global Duchenne Muscular Dystrophy Drugs Sales and Revenue (2018-2028)
3.2 Largest Application for Duchenne Muscular Dystrophy Drugs (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Duchenne Muscular Dystrophy Drugs Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Duchenne Muscular Dystrophy Drugs Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Duchenne Muscular Dystrophy Drugs Average Price Trend
13.1 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in US (2018-2022)
13.2 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in Europe (2018-2022)
13.3 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in China (2018-2022)
13.4 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in Japan (2018-2022)
13.5 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in India (2018-2022)
13.6 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in Korea (2018-2022)
13.7 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Duchenne Muscular Dystrophy Drugs Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Duchenne Muscular Dystrophy Drugs
15. Duchenne Muscular Dystrophy Drugs Competitive Landscape
15.1 Biogen
15.1.1 Biogen Company Profiles
15.1.2 Biogen Product Introduction
15.1.3 Biogen Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Roche
15.2.1 Roche Company Profiles
15.2.2 Roche Product Introduction
15.2.3 Roche Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Daiichi Sankyo
15.3.1 Daiichi Sankyo Company Profiles
15.3.2 Daiichi Sankyo Product Introduction
15.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Pfizer
15.4.1 Pfizer Company Profiles
15.4.2 Pfizer Product Introduction
15.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Cumberland Pharmaceuticals
15.5.1 Cumberland Pharmaceuticals Company Profiles
15.5.2 Cumberland Pharmaceuticals Product Introduction
15.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Santhera Pharmaceuticals
15.6.1 Santhera Pharmaceuticals Company Profiles
15.6.2 Santhera Pharmaceuticals Product Introduction
15.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Taiho Pharmaceutical
15.7.1 Taiho Pharmaceutical Company Profiles
15.7.2 Taiho Pharmaceutical Product Introduction
15.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Teijin Pharma
15.8.1 Teijin Pharma Company Profiles
15.8.2 Teijin Pharma Product Introduction
15.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 Akashi Therapeutics
15.9.1 Akashi Therapeutics Company Profiles
15.9.2 Akashi Therapeutics Product Introduction
15.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 Sarepta Therapeutics
15.10.1 Sarepta Therapeutics Company Profiles
15.10.2 Sarepta Therapeutics Product Introduction
15.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
15.11 BioMarin
15.12 Fibrogen Inc
15.13 Nobelpharma Co. Ltd
15.14 Eloxx Pharmaceuticals
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Duchenne Muscular Dystrophy Drugs Industry (Volume)
Figure 2. Duchenne Muscular Dystrophy Drugs Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2022
Figure 5. US Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Duchenne Muscular Dystrophy Drugs Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Duchenne Muscular Dystrophy Drugs Revenue, by Type (Million USD) (2018-2028)
Table 4. Duchenne Muscular Dystrophy Drugs Sales, by Type (K Unit) (2018-2028)
Table 5. Duchenne Muscular Dystrophy Drugs Sales (K Unit) by Application (2018-2028)
Table 6. Duchenne Muscular Dystrophy Drugs Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Duchenne Muscular Dystrophy Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Duchenne Muscular Dystrophy Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Duchenne Muscular Dystrophy Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Duchenne Muscular Dystrophy Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Duchenne Muscular Dystrophy Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Duchenne Muscular Dystrophy Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Duchenne Muscular Dystrophy Drugs Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Biogen Profiles
Table 61. Biogen Duchenne Muscular Dystrophy Drugs Product Introduction
Table 62. Biogen Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Biogen Strategic initiatives
Table 64. Roche Profiles
Table 65. Roche Duchenne Muscular Dystrophy Drugs Product Introduction
Table 66. Roche Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Roche Strategic initiatives
Table 68. Daiichi Sankyo Profiles
Table 69. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product Introduction
Table 70. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Daiichi Sankyo Strategic initiatives
Table 72. Pfizer Profiles
Table 73. Pfizer Duchenne Muscular Dystrophy Drugs Product Introduction
Table 74. Pfizer Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Pfizer Strategic initiatives
Table 76. Cumberland Pharmaceuticals Profiles
Table 77. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Introduction
Table 78. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Cumberland Pharmaceuticals Strategic initiatives
Table 80. Santhera Pharmaceuticals Profiles
Table 81. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Introduction
Table 82. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Santhera Pharmaceuticals Strategic initiatives
Table 84. Taiho Pharmaceutical Profiles
Table 85. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product Introduction
Table 86. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Taiho Pharmaceutical Strategic initiatives
Table 88. Teijin Pharma Profiles
Table 89. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product Introduction
Table 90. Teijin Pharma Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Teijin Pharma Strategic initiatives
Table 92. Akashi Therapeutics Profiles
Table 93. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product Introduction
Table 94. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Akashi Therapeutics Strategic initiatives
Table 97. Sarepta Therapeutics Profiles
Table 98. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product Introduction
Table 99. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Sarepta Therapeutics Strategic initiatives
Table 101. BioMarin Profiles
Table 102. BioMarin Duchenne Muscular Dystrophy Drugs Product Introduction
Table 103. BioMarin Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. BioMarin Strategic initiatives
Table 105. Fibrogen Inc Profiles
Table 106. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product Introduction
Table 107. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 108. Fibrogen Inc Strategic initiatives
Table 109. Nobelpharma Co. Ltd Profiles
Table 110. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product Introduction
Table 111. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 112. Nobelpharma Co. Ltd Strategic initiatives
Table 113. Eloxx Pharmaceuticals Profiles
Table 114. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Introduction
Table 115. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 116. Eloxx Pharmaceuticals Strategic initiatives
